SAN DIEGO, Sept. 17, 2018 /PRNewswire/ -- Halozyme
Therapeutics, Inc. (NASDAQ: HALO) today announced that Roche has
received approval from Health Canada for a subcutaneous (SC)
formulation of trastuzumab (Herceptin SC) for the treatment of
patients with HER2-positive breast cancer. This is a co-formulation
with Halozyme's proprietary recombinant human hyaluronidase enzyme
(ENHANZE® technology).
"We are pleased that the subcutaneous formulation of trastuzumab
(Herceptin SC) has been approved in Canada," said Dr. Helen Torley, president and chief executive
officer. "Patients and health care providers will now have another
treatment option with the potential for a reduced administration
time."
The U.S. Food and Drug Administration accepted a Biologics
License Application from Genentech for a subcutaneous (SC)
formulation of trastuzumab (Herceptin SC) in July 2018.
About ENHANZE® Technology
Halozyme's proprietary ENHANZE® drug-delivery technology
is based on its patented recombinant human hyaluronidase enzyme
(rHuPH20). rHuPH20 has been shown to remove traditional limitations
on the volume of biologics that can be delivered subcutaneously
(just under the skin). By using rHuPH20, some biologics and
compounds that are administered intravenously may instead be
delivered subcutaneously. ENHANZE may also benefit subcutaneous
biologics by reducing the need for multiple injections. This
delivery has been shown in studies to reduce health care
practitioner time required for administration and shorten time for
drug administration.
About Halozyme
Halozyme Therapeutics is a
biotechnology company focused on developing and commercializing
novel oncology therapies that target the tumor microenvironment.
Halozyme's lead proprietary program, investigational drug
pegvorhyaluronidase alfa (PEGPH20), applies a unique approach to
targeting solid tumors, allowing increased access of
co-administered cancer drug therapies to the tumor in animal
models. PEGPH20 is currently in development for the treatment of
several cancers and has the potential to be used in combination
with different types of cancer therapies. In addition to its
proprietary product portfolio, Halozyme has established
value-driving partnerships with leading pharmaceutical companies
including Roche, Baxalta, Pfizer, Janssen, AbbVie, Lilly,
Bristol-Myers Squibb and Alexion for its ENHANZE® drug
delivery technology. Halozyme is headquartered in San Diego. For more information visit
www.halozyme.com.
Halozyme Safe Harbor Statement
In addition to
historical information, the statements set forth above include
forward-looking statements (including, without limitation,
statements concerning the Company's future expectations and plans
for growth in 2018, entering into new collaboration agreements, the
development and commercialization of product candidates, including
timing of clinical trial results announcements and future
development and commercial activities of our collaboration
partners, the potential benefits and attributes of such product
candidates and expected financial outlook for 2018) that involve
risk and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. The
forward-looking statements are typically, but not always,
identified through use of the words "believe," "enable," "may,"
"will," "could," "intends," "estimate," "anticipate," "plan,"
"predict," "probable," "potential," "possible," "should,"
"continue," and other words of similar meaning. Actual results
could differ materially from the expectations contained in
forward-looking statements as a result of several factors,
including unexpected expenditures and costs, unexpected
fluctuations or changes in revenues, including revenues from
collaborators, unexpected delays in entering into new collaboration
agreements, unexpected results or delays in development of product
candidates, including delays in clinical trial patient enrollment
and development activities of our collaboration partners, and
regulatory review, regulatory approval requirements, unexpected
adverse events and competitive conditions. These and other factors
that may result in differences are discussed in greater detail in
the Company's Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on August 7, 2018.
Contacts:
Robert H.
Uhl
Managing Director
Westwicke Partners, LLC
858-356-5932
robert.uhl@westwicke.com
Laurie Stelzer
858-704-8222
ir@halozyme.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/halozyme-announces-approval-of-subcutaneous-formulation-of-trastuzumab-herceptin-in-canada-300713267.html
SOURCE Halozyme Therapeutics, Inc.